Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751486 | 0.89 | CHRM3 (0.55) | CHRM3ADRB2 | |
| SCHEMBL643481 | 0.88 | CHRM3 (0.53) | CHRM3ADRB2 | |
| SCHEMBL4432812 | 0.85 | CHRM3 (0.59) | CHRM3ADRB2 | |
| SCHEMBL642707 | 0.83 | CHRM2 (0.68) | CHRM3ADRB2 | |
| SCHEMBL2641188 | 0.82 | CHRM2 (0.56) | CHRM3ADRB2 | |
| SCHEMBL643323 | 0.81 | CHRM3 (0.69) | CHRM3 | |
| SCHEMBL7000832 | 0.81 | CHRM3 (0.60) | CHRM3ADRB2 | |
| SCHEMBL12309455 | 0.81 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3761022 | 0.80 | CHRM3 (0.66) | CHRM3ADRB2 | |
| SCHEMBL644494 | 0.80 | CHRM3 (0.58) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119796-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281851-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM5 | CHRM3 2/4885ADRB2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.